CY1121957T1 - Χρηση της αδελμιδρολης στη θεραπεια επιθηλιακων δυσλειτουργιων - Google Patents
Χρηση της αδελμιδρολης στη θεραπεια επιθηλιακων δυσλειτουργιωνInfo
- Publication number
- CY1121957T1 CY1121957T1 CY20191100689T CY191100689T CY1121957T1 CY 1121957 T1 CY1121957 T1 CY 1121957T1 CY 20191100689 T CY20191100689 T CY 20191100689T CY 191100689 T CY191100689 T CY 191100689T CY 1121957 T1 CY1121957 T1 CY 1121957T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- dysfunctions
- adelmidrole
- epithelial
- adelmidrol
- Prior art date
Links
- 230000004064 dysfunction Effects 0.000 title 1
- PAHZPHDAJQIETD-UHFFFAOYSA-N adelmidrol Chemical compound OCCNC(=O)CCCCCCCC(=O)NCCO PAHZPHDAJQIETD-UHFFFAOYSA-N 0.000 abstract 3
- 229950005297 adelmidrol Drugs 0.000 abstract 3
- 229950007031 palmidrol Drugs 0.000 abstract 2
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 abstract 2
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 abstract 1
- 101000958771 Homo sapiens N-acylethanolamine-hydrolyzing acid amidase Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102100038360 N-acylethanolamine-hydrolyzing acid amidase Human genes 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007360 epithelial dysfunction Effects 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009092 tissue dysfunction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
Abstract
Το αντικείμενο της παρούσας εφεύρεσης είναι η Αδελμιδρόλη στη θεραπεία των επιθηλιακών δυσλειτουργιών. Συγκεκριμένα, η παρούσα εφεύρεση αναφέρεται στην Αδελμιδρόλη για χρήση στη θεραπεία δυσλειτουργιών του επιθηλιακού ιστού σε άνθρωπο ή ζώο, όπου η εν λόγω Αδελμιδρόλη προκαλεί αύξηση των ενδογενών επιπέδων της Παλμιτοϋλαιθανολαμίδης χωρίς αναστολή της δραστικότητας των ενζύμων FAAH και ΝΑΑΑ αποικοδόμησης της Παλμιτοϋλαιθανολαμίδης.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20141245 | 2014-07-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121957T1 true CY1121957T1 (el) | 2020-10-14 |
Family
ID=51904027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100689T CY1121957T1 (el) | 2014-07-08 | 2019-07-01 | Χρηση της αδελμιδρολης στη θεραπεια επιθηλιακων δυσλειτουργιων |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20160008301A1 (el) |
| EP (1) | EP2965765B1 (el) |
| JP (1) | JP6752001B2 (el) |
| KR (1) | KR102490825B1 (el) |
| CN (1) | CN105250252A (el) |
| AU (1) | AU2015203809B2 (el) |
| CA (1) | CA2896435C (el) |
| CY (1) | CY1121957T1 (el) |
| DK (1) | DK2965765T3 (el) |
| ES (1) | ES2740928T3 (el) |
| HK (1) | HK1217913A1 (el) |
| HU (1) | HUE044801T2 (el) |
| PL (1) | PL2965765T3 (el) |
| PT (1) | PT2965765T (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITUB20154849A1 (it) * | 2015-10-30 | 2017-04-30 | Epitech Group S P A | ADELMIDROL PER L'USO NELLE PATOLOGIE CARATTERIZZATE DA INSUFFICIENTE AGONISMO DEL RECETTORE PPAR-gamma |
| RU2610557C1 (ru) * | 2016-01-13 | 2017-02-13 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт глазных болезней" | Способ профилактики избыточного рубцевания дакриостомы после дакриоцисториностомии |
| CN113082029B (zh) * | 2021-03-02 | 2022-07-15 | 浙大宁波理工学院 | 一种伤口清洗消毒剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1252866B (it) * | 1991-12-31 | 1995-06-28 | Lifegroup Spa | N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica |
| ATE290858T1 (de) | 1999-08-06 | 2005-04-15 | Innovet Italia Srl | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin |
| ATE286379T1 (de) * | 1999-08-06 | 2005-01-15 | Innovet Italia Srl | Verwendung von n,n'-bis(2-hydroxyethyl)- nonandiamid (aldemidrol) als kosmetisches mittel |
| DE60219148T2 (de) * | 2002-06-26 | 2007-12-06 | Innovet Italia S.R.L. | Pharmazeutische Zusammensetzung zur Verhinderung der Entwicklung und Progression von mykotischen Hautoberflächenerkrankungen |
| EP1714644B1 (en) * | 2005-04-19 | 2012-08-08 | Innovet Italia S.r.l. | Pharmaceutical compositions for the treatment of chronic ulcerations |
| ATE464890T1 (de) * | 2006-03-28 | 2010-05-15 | Epitech Group Srl | Eine pharmazeutische zusammensetzung zur behandlung von pathologien, die durch die allgemeine immunantwort verursacht werden |
| PL2475352T5 (pl) | 2009-09-07 | 2019-02-28 | Epitech Group S.P.A. | Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji |
| US9512091B2 (en) * | 2012-02-17 | 2016-12-06 | Epitech Group S.R.L. | Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases |
-
2015
- 2015-07-07 DK DK15175689.7T patent/DK2965765T3/da active
- 2015-07-07 CA CA2896435A patent/CA2896435C/en active Active
- 2015-07-07 PL PL15175689T patent/PL2965765T3/pl unknown
- 2015-07-07 ES ES15175689T patent/ES2740928T3/es active Active
- 2015-07-07 PT PT15175689T patent/PT2965765T/pt unknown
- 2015-07-07 EP EP15175689.7A patent/EP2965765B1/en active Active
- 2015-07-07 US US14/793,165 patent/US20160008301A1/en not_active Abandoned
- 2015-07-07 HU HUE15175689 patent/HUE044801T2/hu unknown
- 2015-07-08 CN CN201510398756.0A patent/CN105250252A/zh active Pending
- 2015-07-08 AU AU2015203809A patent/AU2015203809B2/en active Active
- 2015-07-08 JP JP2015137093A patent/JP6752001B2/ja active Active
- 2015-07-08 KR KR1020150097205A patent/KR102490825B1/ko active IP Right Grant
-
2016
- 2016-05-25 HK HK16105943.9A patent/HK1217913A1/zh unknown
-
2017
- 2017-04-07 US US15/482,129 patent/US20170209395A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/374,912 patent/US11491122B2/en active Active
- 2019-07-01 CY CY20191100689T patent/CY1121957T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016028022A (ja) | 2016-02-25 |
| US20190224145A1 (en) | 2019-07-25 |
| HK1217913A1 (zh) | 2017-01-27 |
| CA2896435C (en) | 2023-08-22 |
| EP2965765A1 (en) | 2016-01-13 |
| US11491122B2 (en) | 2022-11-08 |
| PL2965765T3 (pl) | 2019-11-29 |
| JP6752001B2 (ja) | 2020-09-09 |
| US20160008301A1 (en) | 2016-01-14 |
| KR20160006124A (ko) | 2016-01-18 |
| PT2965765T (pt) | 2019-07-10 |
| DK2965765T3 (da) | 2019-07-22 |
| ES2740928T3 (es) | 2020-02-07 |
| KR102490825B1 (ko) | 2023-01-20 |
| EP2965765B1 (en) | 2019-05-08 |
| AU2015203809B2 (en) | 2020-02-20 |
| HUE044801T2 (hu) | 2019-11-28 |
| CA2896435A1 (en) | 2016-01-08 |
| CN105250252A (zh) | 2016-01-20 |
| US20170209395A1 (en) | 2017-07-27 |
| AU2015203809A1 (en) | 2016-01-21 |
| BR102015016445A2 (pt) | 2016-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122981T1 (el) | Συνθεσεις για διαμορφωση της εκφρασης του c9orf72 | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1122602T1 (el) | Αντιμετωπιση των nafld και nash | |
| CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| CY1122480T1 (el) | Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας | |
| CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
| CR20190350A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| MD3209310T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
| BR112016026378A2 (pt) | formulações e métodos para tratamento com queratina | |
| EA201700464A1 (ru) | Производные майтанзиноида, их конъюгаты и способы использования | |
| BR112017006664A2 (pt) | terapias de combinação | |
| CL2018002698A1 (es) | Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a | |
| PE20180243A1 (es) | Composiciones que comprenden cepas bacterianas | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| BR112017005002A2 (pt) | macropinocitose de anticorpos anti-cd46 humanos e agentes terapêuticos dirigidos contra o câncer. | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| BR112018016450A2 (pt) | composições intensificadoras de vcn e métodos de uso das mesmas | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения |